Altawalbeh SM, Wateska AR, Nowalk MP, Lin CJ, et al. Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older. Vaccine 2024 Apr 4:S0264-410X(24)00404-3. doi: 10.1016/j.vaccine.2024.
PMID: 38580515